Bibliometric analysis of the research hotspots and trends of retinoblastoma from 2015 to 2024_Chinese Journal of Ocular Fundus Diseases

Authors：

Yuan Duo ¹ , Zhang Yulin ² , Zhao Xinyu ² , Cui Kaixuan ² , Wu Zhenquan ² , Yu Zhen ² , Chi Wei ² ,  Zhang Guoming ²

1. The Second Clinical Medical College of Jinan University, Shenzhen Eye Hospital, Shenzhen 518040, China;
2. Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University, Shenzhen 518040, China;

Corresponding author：

Zhang Guoming, Email: zhangguoming@sz-eyes.com

Keywords：

Retinoblastoma; Research Trends; Research Hotspots; Visual Analysis

DOI：

10.3760/cma.j.cn511434-20250324-00126

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the current status, research hotspots, and future trends in the field of retinoblastoma (RB). Methods Using the Web of Science Core Collection SSCI and SCI-Expanded as data sources, relevant RB literature from January 2015 to November 2024 was retrieved. The bibliometric analysis software CiteSpace 6.2.R6 was employed to perform visual analyses of countries/regions, institutions, journals, authors, co-cited references, and keywords. Results A total of 5 042 relevant publications were identified. Annual publication numbers in this field consistently exceeded 400, peaking at 565 in 2021. The United States contributed the highest number of publications, with 1 600 articles (31.73%). Among institutions, Harvard University ranked first with 167 publications (3.31%). Abramson DH of Memorial Sloan Kettering Cancer Center published the most papers (75). Nature (United Kingdom) received the highest citation count (2, 349). The highest betweenness centrality was observed for the United States (0.14) among countries/regions, Shanghai Jiao Tong University (0.21) among institutions, and Berry JL of Children’s Hospital Los Angeles (0.21) at the author level. Co-citation and keyword analyses revealed that RB research hotspots are shifting from a focus on basic molecular mechanisms, such as the cell cycle and RB protein, toward advanced therapeutic strategies, such as intra-arterial chemotherapy and nanoparticle-based drug delivery. Emerging keywords such as complexity, chemoresistance and carboplatin indicate that future studies will focus on optimising diagnosis and treatment. Conclusions From 2015 to 2024, RB research displayed a sustained growth trend, with the United States and its institutions and scholars contributing the most publications. The research focus has shifted from the exploration of molecular mechanisms to the optimization of precise treatment strategies, among which the application of nanotechnology and the resolution of drug resistance mechanisms will become key breakthrough directions.

1.	Fabian ID, Sagoo MS. Understanding retinoblastoma: epidemiology and genetics[J]. Community Eye Health, 2018, 31(101): 7.
2.	Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al. Retinoblastoma[J/OL]. Orphanet J Rare Dis, 2006, 1: 31[2006-08-25]. https://pubmed.ncbi.nlm.nih.gov/16934146/. DOI: 10.1186/1750-1172-1-31.
3.	Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes: association with national income level[J]. Ophthalmology, 2021, 128(6): 740-753. DOI: 10.1016/j.ophtha.2020.09.032.
4.	Wong JR, Tucker MA, Kleinerman RA, et al. Retinoblastoma incidence patterns in the US SEER Program[J]. JAMA Ophthalmol, 2014, 132(4): 478-483. DOI: 10.1001/jamaophthalmol.2013.8001.
5.	Kaliki S, Vempuluru VS, Mohamed A, et al. Retinoblastoma in Asia: retinoblastoma in Asia[J]. Ophthalmology, 2024, 131(4): 468-477. DOI: 10.1016/j.ophtha.2023.10.015.
6.	Berry JL, Pike S, Rajagopalan A, et al. Retinoblastoma outcomes in the Americas: a prospective analysis of 491 children with retinoblastoma from 23 American countries[J]. Am J Ophthalmol, 2024, 260: 91-101. DOI: 10.1016/j.ajo.2023.11.004.
7.	Wang R, Zuo G, Li K, et al. Systematic bibliometric and visualized analysis of research hotspots and trends on the application of artificial intelligence in diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2022, 13: 1036426[2022-10-31]. https://pubmed.ncbi.nlm.nih.gov/36387891/. DOI: 10.3389/fendo.2022.1036426.
8.	Cuocolo R, Ponsiglione A, Dell’Aversana S, et al. The cardiac conundrum: a systematic review and bibliometric analysis of authorship in cardiac magnetic resonance imaging studies[J]. Insights Imaging, 2020, 11(1): 42. DOI: 10.1186/s13244-020-00850-1.
9.	Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature[J]. J Assoc Inf Sci Technol, 2006, 57(3): 359-377. DOI: 10.1002/asi.20317.
10.	Singh VK, Singh P, Karmakar M, et al. The journal coverage of Web of Science, Scopus and Dimensions: a comparative analysis[J]. Scientometrics, 2021, 126(6): 5113-5142. DOI: 10.1007/s11192-021-03948-5.
11.	Birkle C, Pendlebury DA, Schnell J, et al. Web of Science as a data source for research on scientific and scholarly activity[J]. Quant Sci Stud, 2020, 1(1): 363-376. DOI: 10.1162/qss_a_00018.
12.	陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.Chen Y, Chen CM, Liu ZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Stud Sci Sci, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.
13.	Zhou M, Tang J, Fan J, et al. Recent progress in retinoblastoma: pathogenesis, presentation, diagnosis and management[J/OL]. Asia Pac J Ophthalmol (Phila), 2024, 13(2): 100058[2024-04-12]. https://pubmed.ncbi.nlm.nih.gov/38615905/. DOI: 10.1016/j.apjo.2024.100058.
14.	Field MG, Kuznetsoff JN, Zhang MG, et al. RB1 loss triggers dependence on ESRRG in retinoblastoma[J/OL]. Sci Adv, 2022, 8(33): eabm8466[2022-08-19]. https://pubmed.ncbi.nlm.nih.gov/35984874/. DOI: 10.1126/sciadv.abm8466.
15.	Dryja TP, Rapaport JM, Joyce JM, et al. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas[J]. Proc Natl Acad Sci USA, 1986, 83(19): 7391-7394. DOI: 10.1073/pnas.83.19.7391.
16.	Marzi MJ, Puggioni EMR, Dall’Olio V, et al. Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation[J]. J Cell Biol, 2012, 199(1): 77-95. DOI: 10.1083/jcb.201206033.
17.	Pan W, Chaudhary N, Sedig L, et al. Scleral ectasia stabilization following intra-arterial chemotherapy in an eye with recurrent retinoblastoma[J/OL]. Am J Ophthalmol Case Rep, 2023, 32: 101941[2023-10-13]. https://pubmed.ncbi.nlm.nih.gov/37915729/. DOI: 10.1016/j.ajoc.2023.101941.
18.	Gao Y, Du P. miR-889-3p targeting BMPR2 promotes the development of retinoblastoma via JNK/MAPK/ERK signaling[J/OL]. Sci Rep, 2024, 14(1): 7277[2024-04-27]. https://pubmed.ncbi.nlm.nih.gov/38538669/. DOI: 10.1038/s41598-024-57924-z.
19.	Mandal M, Banerjee I, Mandal M. Nanoparticle-mediated gene therapy as a novel strategy for the treatment of retinoblastoma[J/OL]. Colloids Surf B Biointerfaces, 2022, 220: 112899[2022-10-04]. https://pubmed.ncbi.nlm.nih.gov/36252537/. DOI: 10.1016/j.colsurfb.2022.112899.
20.	Ahmed F, Ali MJ, Kondapi AK. Carboplatin loaded protein nanoparticles exhibit improved anti-proliferative activity in retinoblastoma cells[J]. Int J Biol Macromol, 2014, 70: 572-582. DOI: 10.1016/j.ijbiomac.2014.07.041.
21.	Singh HP, Shayler DWH, Fernandez GE, et al. An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc-initiated retinoblastoma[J/OL]. Proc Natl Acad Sci USA, 2022, 119(6): e2200721119[2022-07-12]. https://pubmed.ncbi.nlm.nih.gov/35867756/. DOI: 10.1073/pnas.2200721119.
22.	Almontaser E, Ritchie C, Madison J, et al. Perioperative care of children undergoing intra-arterial chemotherapy for retinoblastoma[J]. J Perianesth Nurs, 2019, 34(5): 476-482. DOI: 10.1016/j.jopan.2018.09.013.
23.	Yang J, Li Y, Han Y, et al. Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma[J/OL]. Cell Death Dis, 2021, 12(12): 1100[2021-11-23]. https://pubmed.ncbi.nlm.nih.gov/34815392/. DOI: 10.1038/s41419-021-04390-4.
24.	Wen X, Ding T, Li F, et al. Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis[J/OL]. Commun Biol, 2022, 5(1): 1036[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36175480/. DOI: 10.1038/s42003-022-04007-2.
25.	Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma[J]. Proc Natl Acad Sci USA, 1971, 68(4): 820-823. DOI: 10.1073/pnas.68.4.820.
26.	Li K, Deng Z, Lei C, et al. The role of oxidative stress in tumorigenesis and progression[J/OL]. Cells, 2024, 13(5): 441[2024-04-02]. https://pubmed.ncbi.nlm.nih.gov/38474405/. DOI: 10.3390/cells13050441.
27.	Ye Q, Zeng Z, Liang X, et al. Quercetin suppresses retinoblastoma cell proliferation and invasion and facilitates oxidative stress-induced apoptosis through the miR-137/FNDC5 axis[J/OL]. Environ Res, 2023, 237: 116934[2023-11-15]. https://pubmed.ncbi.nlm.nih.gov/37598849/. DOI: 10.1016/j.envres.2023.116934.
28.	Ma X, Li X, Sun Q, et al. Molecular biological research on the pathogenic mechanism of retinoblastoma[J]. Curr Issues Mol Biol, 2024, 46(6): 5307-5321. DOI: 10.3390/cimb46060317.
29.	Huang MF, Wang YX, Chou YT, et al. Therapeutic strategies for RB1-deficient cancers: intersecting gene regulation and targeted therapy[J/OL]. Cancers, 2024, 16(8): 1558[2024-04-19]. https://pubmed.ncbi.nlm.nih.gov/38672640/. DOI: 10.3390/cancers16081558.
30.	Binné UK, Classon MK, Dick FA, et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit[J]. Nat Cell Biol, 2007, 9(3): 225-232. DOI: 10.1038/ncb1532.
31.	Ji P, Jiang H, Rekhtman K, et al. An Rb-Skp2-p27 pathway mediates acute cell-cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant[J]. Mol Cell, 2004, 16(1): 47-58. DOI: 10.1016/j.molcel.2004.09.029.
32.	Neupane R, Gaudana R, Boddu SHS. Imaging techniques in the diagnosis and management of ocular tumors: prospects and challenges[J/OL]. AAPS J, 2018, 20(6): 97[2018-09-05]. https://pubmed.ncbi.nlm.nih.gov/30187172/. DOI: 10.1208/s12248-018-0259-9.
33.	Jenkinson H. Retinoblastoma: diagnosis and management--the UK perspective[J]. Arch Dis Child, 2015, 100(11): 1070-1075. DOI: 10.1136/archdischild-2014-306208.
34.	Chen F, Si P, de la Zerda A , et al. Gold nanoparticles to enhance ophthalmic imaging[J]. Biomater Sci, 2021, 9(2): 367-390. DOI: 10.1039/d0bm01063d.
35.	Golabchi K, Soleimani-Jelodar R, Aghadoost N, et al. MicroRNAs in retinoblastoma: potential diagnostic and therapeutic biomarkers[J]. J Cell Physiol, 2018, 233(6): 3016-3023. DOI: 10.1002/jcp.26070.
36.	Zhao JJ, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis[J]. Childs Nerv Syst, 2009, 25(1): 13-20. DOI: 10.1007/s00381-008-0701-x.
37.	Beta M, Khetan V, Biswas J, et al. EpCAM knockdown alters microRNA expression in retinoblastoma—functional implication of EpCAM-regulated miRNA in tumor progression[J]. PLOS ONE, 2014, 9(12): e114800. DOI: 10.1371/journal.pone.0114800.
38.	Zhou C, Wen X, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma[J]. Ophthalmology, 2022, 129(2): 209-219. DOI: 10.1016/j.ophtha.2021.09.002.
39.	Wen X, Fan J, Jin M, et al. Intravenous versus super-selective intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial[J]. Lancet Child Adolesc Health, 2023, 7(9): 613-620. DOI: 10.1016/S2352-4642(23)00141-4.
40.	Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy[J]. Indian J Ophthalmol, 2015, 63(2): 103-109. DOI: 10.4103/0301-4738.154369.
41.	Abramson DH, Marr BP, Francis JH, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy)[J/OL]. PLoS One, 2016, 11(5): e0156806[2016-06-03]. https://pubmed.ncbi.nlm.nih.gov/27258771/. DOI: 10.1371/journal.pone.0156806.
42.	Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular and intravitreal chemotherapy[J]. Curr Opin Ophthalmol, 2014, 25(5): 374-385. DOI: 10.1097/ICU.0000000000000091.
43.	Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds and vitreous seeds[J]. Arch Ophthalmol, 2011, 129(11): 1399-1406. DOI: 10.1001/archophthalmol.2011.150.
44.	Onugwu AL, Ugorji OL, Ufondu CA, et al. Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects[J]. Nanoscale Adv, 2023, 5(6): 4628-4648. DOI: 10.1039/d3na00462g.
45.	Byroju VV, Nadukkandy AS, Cordani M, et al. Retinoblastoma: present scenario and future challenges[J/OL]. Cell Commun Signal, 2023, 21(1): 226[2023-09-04]. https://pubmed.ncbi.nlm.nih.gov/37667345/. DOI: 10.1186/s12964-023-01223-z.
46.	Suthapot P, Chiangjong W, Chaiyawat P, et al. Genomics-driven precision medicine in pediatric solid tumors[J/OL]. Cancers (Basel), 2023, 15(5): 1418[2023-02-23]. https://pubmed.ncbi.nlm.nih.gov/36900212/. DOI: 10.3390/cancers15051418.
47.	Lima RV, Arruda MP, Muniz MCR, et al. Artificial intelligence methods in diagnosis of retinoblastoma based on fundus imaging: a systematic review and meta-analysis[J]. Graefe’s Arch Clin Exp Ophthalmol, 2025, 263(2): 547-553. DOI: 10.1007/s00417-024-06643-2.
48.	Ye R, Yuan Q, You W, et al. Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning[J/OL]. Sci Rep, 2024, 14(1): 31355[2024-12-28]. https://pubmed.ncbi.nlm.nih.gov/39733097/. DOI: 10.1038/s41598-024-82789-7.
49.	Vempuluru VS, Viriyala R, Ayyagari V, et al. Artificial intelligence and machine learning in ocular oncology, retinoblastoma (ArMOR): experience with a multiracial cohort[J]. Cancers, 2024, 16(20): 3516. DOI: 10.3390/cancers16203516.
50.	Jin Q, Liu Q, Hu Y, et al. Prediction of mortality in retinoblastoma using machine learning based on SEER database[J]. J Clin Oncol, 2024, 42(15): 1234-1245. DOI: 10.1200/JCO.2024.42.15.1234.
51.	Wong ES, Choy RW, Zhang Y, et al. Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors[J/OL]. Lancet Glob Health, 2022, 10(3): e380-e389[2022-01-27]. https://pubmed.ncbi.nlm.nih.gov/35093202/. DOI: 10.1016/S2214-109X(21)00555-6.

1. Fabian ID, Sagoo MS. Understanding retinoblastoma: epidemiology and genetics[J]. Community Eye Health, 2018, 31(101): 7.
2. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al. Retinoblastoma[J/OL]. Orphanet J Rare Dis, 2006, 1: 31[2006-08-25]. https://pubmed.ncbi.nlm.nih.gov/16934146/. DOI: 10.1186/1750-1172-1-31.
3. Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes: association with national income level[J]. Ophthalmology, 2021, 128(6): 740-753. DOI: 10.1016/j.ophtha.2020.09.032.
4. Wong JR, Tucker MA, Kleinerman RA, et al. Retinoblastoma incidence patterns in the US SEER Program[J]. JAMA Ophthalmol, 2014, 132(4): 478-483. DOI: 10.1001/jamaophthalmol.2013.8001.
5. Kaliki S, Vempuluru VS, Mohamed A, et al. Retinoblastoma in Asia: retinoblastoma in Asia[J]. Ophthalmology, 2024, 131(4): 468-477. DOI: 10.1016/j.ophtha.2023.10.015.
6. Berry JL, Pike S, Rajagopalan A, et al. Retinoblastoma outcomes in the Americas: a prospective analysis of 491 children with retinoblastoma from 23 American countries[J]. Am J Ophthalmol, 2024, 260: 91-101. DOI: 10.1016/j.ajo.2023.11.004.
7. Wang R, Zuo G, Li K, et al. Systematic bibliometric and visualized analysis of research hotspots and trends on the application of artificial intelligence in diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2022, 13: 1036426[2022-10-31]. https://pubmed.ncbi.nlm.nih.gov/36387891/. DOI: 10.3389/fendo.2022.1036426.
8. Cuocolo R, Ponsiglione A, Dell’Aversana S, et al. The cardiac conundrum: a systematic review and bibliometric analysis of authorship in cardiac magnetic resonance imaging studies[J]. Insights Imaging, 2020, 11(1): 42. DOI: 10.1186/s13244-020-00850-1.
9. Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature[J]. J Assoc Inf Sci Technol, 2006, 57(3): 359-377. DOI: 10.1002/asi.20317.
10. Singh VK, Singh P, Karmakar M, et al. The journal coverage of Web of Science, Scopus and Dimensions: a comparative analysis[J]. Scientometrics, 2021, 126(6): 5113-5142. DOI: 10.1007/s11192-021-03948-5.
11. Birkle C, Pendlebury DA, Schnell J, et al. Web of Science as a data source for research on scientific and scholarly activity[J]. Quant Sci Stud, 2020, 1(1): 363-376. DOI: 10.1162/qss_a_00018.
12. 陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.Chen Y, Chen CM, Liu ZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Stud Sci Sci, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.
13. Zhou M, Tang J, Fan J, et al. Recent progress in retinoblastoma: pathogenesis, presentation, diagnosis and management[J/OL]. Asia Pac J Ophthalmol (Phila), 2024, 13(2): 100058[2024-04-12]. https://pubmed.ncbi.nlm.nih.gov/38615905/. DOI: 10.1016/j.apjo.2024.100058.
14. Field MG, Kuznetsoff JN, Zhang MG, et al. RB1 loss triggers dependence on ESRRG in retinoblastoma[J/OL]. Sci Adv, 2022, 8(33): eabm8466[2022-08-19]. https://pubmed.ncbi.nlm.nih.gov/35984874/. DOI: 10.1126/sciadv.abm8466.
15. Dryja TP, Rapaport JM, Joyce JM, et al. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas[J]. Proc Natl Acad Sci USA, 1986, 83(19): 7391-7394. DOI: 10.1073/pnas.83.19.7391.
16. Marzi MJ, Puggioni EMR, Dall’Olio V, et al. Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation[J]. J Cell Biol, 2012, 199(1): 77-95. DOI: 10.1083/jcb.201206033.
17. Pan W, Chaudhary N, Sedig L, et al. Scleral ectasia stabilization following intra-arterial chemotherapy in an eye with recurrent retinoblastoma[J/OL]. Am J Ophthalmol Case Rep, 2023, 32: 101941[2023-10-13]. https://pubmed.ncbi.nlm.nih.gov/37915729/. DOI: 10.1016/j.ajoc.2023.101941.
18. Gao Y, Du P. miR-889-3p targeting BMPR2 promotes the development of retinoblastoma via JNK/MAPK/ERK signaling[J/OL]. Sci Rep, 2024, 14(1): 7277[2024-04-27]. https://pubmed.ncbi.nlm.nih.gov/38538669/. DOI: 10.1038/s41598-024-57924-z.
19. Mandal M, Banerjee I, Mandal M. Nanoparticle-mediated gene therapy as a novel strategy for the treatment of retinoblastoma[J/OL]. Colloids Surf B Biointerfaces, 2022, 220: 112899[2022-10-04]. https://pubmed.ncbi.nlm.nih.gov/36252537/. DOI: 10.1016/j.colsurfb.2022.112899.
20. Ahmed F, Ali MJ, Kondapi AK. Carboplatin loaded protein nanoparticles exhibit improved anti-proliferative activity in retinoblastoma cells[J]. Int J Biol Macromol, 2014, 70: 572-582. DOI: 10.1016/j.ijbiomac.2014.07.041.
21. Singh HP, Shayler DWH, Fernandez GE, et al. An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc-initiated retinoblastoma[J/OL]. Proc Natl Acad Sci USA, 2022, 119(6): e2200721119[2022-07-12]. https://pubmed.ncbi.nlm.nih.gov/35867756/. DOI: 10.1073/pnas.2200721119.
22. Almontaser E, Ritchie C, Madison J, et al. Perioperative care of children undergoing intra-arterial chemotherapy for retinoblastoma[J]. J Perianesth Nurs, 2019, 34(5): 476-482. DOI: 10.1016/j.jopan.2018.09.013.
23. Yang J, Li Y, Han Y, et al. Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma[J/OL]. Cell Death Dis, 2021, 12(12): 1100[2021-11-23]. https://pubmed.ncbi.nlm.nih.gov/34815392/. DOI: 10.1038/s41419-021-04390-4.
24. Wen X, Ding T, Li F, et al. Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis[J/OL]. Commun Biol, 2022, 5(1): 1036[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36175480/. DOI: 10.1038/s42003-022-04007-2.
25. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma[J]. Proc Natl Acad Sci USA, 1971, 68(4): 820-823. DOI: 10.1073/pnas.68.4.820.
26. Li K, Deng Z, Lei C, et al. The role of oxidative stress in tumorigenesis and progression[J/OL]. Cells, 2024, 13(5): 441[2024-04-02]. https://pubmed.ncbi.nlm.nih.gov/38474405/. DOI: 10.3390/cells13050441.
27. Ye Q, Zeng Z, Liang X, et al. Quercetin suppresses retinoblastoma cell proliferation and invasion and facilitates oxidative stress-induced apoptosis through the miR-137/FNDC5 axis[J/OL]. Environ Res, 2023, 237: 116934[2023-11-15]. https://pubmed.ncbi.nlm.nih.gov/37598849/. DOI: 10.1016/j.envres.2023.116934.
28. Ma X, Li X, Sun Q, et al. Molecular biological research on the pathogenic mechanism of retinoblastoma[J]. Curr Issues Mol Biol, 2024, 46(6): 5307-5321. DOI: 10.3390/cimb46060317.
29. Huang MF, Wang YX, Chou YT, et al. Therapeutic strategies for RB1-deficient cancers: intersecting gene regulation and targeted therapy[J/OL]. Cancers, 2024, 16(8): 1558[2024-04-19]. https://pubmed.ncbi.nlm.nih.gov/38672640/. DOI: 10.3390/cancers16081558.
30. Binné UK, Classon MK, Dick FA, et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit[J]. Nat Cell Biol, 2007, 9(3): 225-232. DOI: 10.1038/ncb1532.
31. Ji P, Jiang H, Rekhtman K, et al. An Rb-Skp2-p27 pathway mediates acute cell-cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant[J]. Mol Cell, 2004, 16(1): 47-58. DOI: 10.1016/j.molcel.2004.09.029.
32. Neupane R, Gaudana R, Boddu SHS. Imaging techniques in the diagnosis and management of ocular tumors: prospects and challenges[J/OL]. AAPS J, 2018, 20(6): 97[2018-09-05]. https://pubmed.ncbi.nlm.nih.gov/30187172/. DOI: 10.1208/s12248-018-0259-9.
33. Jenkinson H. Retinoblastoma: diagnosis and management--the UK perspective[J]. Arch Dis Child, 2015, 100(11): 1070-1075. DOI: 10.1136/archdischild-2014-306208.
34. Chen F, Si P, de la Zerda A , et al. Gold nanoparticles to enhance ophthalmic imaging[J]. Biomater Sci, 2021, 9(2): 367-390. DOI: 10.1039/d0bm01063d.
35. Golabchi K, Soleimani-Jelodar R, Aghadoost N, et al. MicroRNAs in retinoblastoma: potential diagnostic and therapeutic biomarkers[J]. J Cell Physiol, 2018, 233(6): 3016-3023. DOI: 10.1002/jcp.26070.
36. Zhao JJ, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis[J]. Childs Nerv Syst, 2009, 25(1): 13-20. DOI: 10.1007/s00381-008-0701-x.
37. Beta M, Khetan V, Biswas J, et al. EpCAM knockdown alters microRNA expression in retinoblastoma—functional implication of EpCAM-regulated miRNA in tumor progression[J]. PLOS ONE, 2014, 9(12): e114800. DOI: 10.1371/journal.pone.0114800.
38. Zhou C, Wen X, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma[J]. Ophthalmology, 2022, 129(2): 209-219. DOI: 10.1016/j.ophtha.2021.09.002.
39. Wen X, Fan J, Jin M, et al. Intravenous versus super-selective intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial[J]. Lancet Child Adolesc Health, 2023, 7(9): 613-620. DOI: 10.1016/S2352-4642(23)00141-4.
40. Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy[J]. Indian J Ophthalmol, 2015, 63(2): 103-109. DOI: 10.4103/0301-4738.154369.
41. Abramson DH, Marr BP, Francis JH, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy)[J/OL]. PLoS One, 2016, 11(5): e0156806[2016-06-03]. https://pubmed.ncbi.nlm.nih.gov/27258771/. DOI: 10.1371/journal.pone.0156806.
42. Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular and intravitreal chemotherapy[J]. Curr Opin Ophthalmol, 2014, 25(5): 374-385. DOI: 10.1097/ICU.0000000000000091.
43. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds and vitreous seeds[J]. Arch Ophthalmol, 2011, 129(11): 1399-1406. DOI: 10.1001/archophthalmol.2011.150.
44. Onugwu AL, Ugorji OL, Ufondu CA, et al. Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects[J]. Nanoscale Adv, 2023, 5(6): 4628-4648. DOI: 10.1039/d3na00462g.
45. Byroju VV, Nadukkandy AS, Cordani M, et al. Retinoblastoma: present scenario and future challenges[J/OL]. Cell Commun Signal, 2023, 21(1): 226[2023-09-04]. https://pubmed.ncbi.nlm.nih.gov/37667345/. DOI: 10.1186/s12964-023-01223-z.
46. Suthapot P, Chiangjong W, Chaiyawat P, et al. Genomics-driven precision medicine in pediatric solid tumors[J/OL]. Cancers (Basel), 2023, 15(5): 1418[2023-02-23]. https://pubmed.ncbi.nlm.nih.gov/36900212/. DOI: 10.3390/cancers15051418.
47. Lima RV, Arruda MP, Muniz MCR, et al. Artificial intelligence methods in diagnosis of retinoblastoma based on fundus imaging: a systematic review and meta-analysis[J]. Graefe’s Arch Clin Exp Ophthalmol, 2025, 263(2): 547-553. DOI: 10.1007/s00417-024-06643-2.
48. Ye R, Yuan Q, You W, et al. Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning[J/OL]. Sci Rep, 2024, 14(1): 31355[2024-12-28]. https://pubmed.ncbi.nlm.nih.gov/39733097/. DOI: 10.1038/s41598-024-82789-7.
49. Vempuluru VS, Viriyala R, Ayyagari V, et al. Artificial intelligence and machine learning in ocular oncology, retinoblastoma (ArMOR): experience with a multiracial cohort[J]. Cancers, 2024, 16(20): 3516. DOI: 10.3390/cancers16203516.
50. Jin Q, Liu Q, Hu Y, et al. Prediction of mortality in retinoblastoma using machine learning based on SEER database[J]. J Clin Oncol, 2024, 42(15): 1234-1245. DOI: 10.1200/JCO.2024.42.15.1234.
51. Wong ES, Choy RW, Zhang Y, et al. Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors[J/OL]. Lancet Glob Health, 2022, 10(3): e380-e389[2022-01-27]. https://pubmed.ncbi.nlm.nih.gov/35093202/. DOI: 10.1016/S2214-109X(21)00555-6.

Chinese Journal of Ocular Fundus Diseases

Latest ArticlesBibliometric analysis of the research hotspots and trends of retinoblastoma from 2015 to 2024

Abstract Full text Figures/Tables Video References Cited by

Format

Content